Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$116,133 Mln
Revenue (TTM)
$397,958 Mln
Net Profit (TTM)
$4,340 Mln
ROE
0 %
ROCE
61.4 %
P/E Ratio
27.2
P/B Ratio
5
Industry P/E
25.7
EV/EBITDA
18.7
Div. Yield
0.3 %
Debt to Equity
-3.6
Book Value
$--
EPS
$34.8
Face value
--
Shares outstanding
122,487,456
CFO
$41,554.00 Mln
EBITDA
$40,794.00 Mln
Net Profit
$11,403.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
McKesson (MCK)
| 12.2 | -2.8 | 14.1 | 40.5 | 39.5 | 37.5 | 19.8 |
|
BSE Sensex*
| -12.4 | -11.4 | -12.2 | -1.5 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
McKesson (MCK)
| 43.9 | 22.9 | 23.4 | 50.9 | 42.9 | 25.7 | 25.2 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
McKesson (MCK)
|
920.4 | 116,133.4 | 397,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 |
| 208.3 | 388,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 351.5 | 197,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 | |
| 59.4 | 120,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 918.1 | 881,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 | |
| 141.3 | 179,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 | |
| 237.3 | 582,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 114.5 | 285,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 149.8 | 296,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 | |
| 27.3 | 151,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S.... Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas. Read more
CEO & Director
Mr. Brian S. Tyler Ph.D.
CEO & Director
Mr. Brian S. Tyler Ph.D.
Headquarters
Irving, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of McKesson Corporation (MCK) is $920.35 (NYSE) as of 18-Mar-2026 16:02 EDT. McKesson Corporation (MCK) has given a return of 39.46% in the last 3 years.
The P/E ratio of McKesson Corporation (MCK) is 27.17 times as on 13-Mar-2026, a 6 premium to its peers’ median range of 25.70 times.
The P/B ratio of McKesson Corporation (MCK) is 5.04 times as on 13-Mar-2026, a 10 discount to its peers’ median range of 5.63 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
25.71
|
-40.85
|
|
2024
|
23.53
|
-35.84
|
|
2023
|
13.80
|
-26.46
|
|
2022
|
41.00
|
-20.10
|
|
2021
|
-6.90
|
-1,490.66
|
The 52-week high and low of McKesson Corporation (MCK) are Rs 999.00 and Rs 637.00 as of 19-Mar-2026.
McKesson Corporation (MCK) has a market capitalisation of $ 116,133 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in McKesson Corporation (MCK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-21.54
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.